Neuroinflammation and nociception in a dish

Funding available until: 20 April 2017

Summary | Background | Current state of the art
What could your Solution be used for? | Collaboration | 3Rs impact | References

Summary

Researchers from the Department of Veterinary Sciences, University of Turin, Italy are seeking partners to help further develop and validate innovative spinal cord slice platforms (SCSPs) for studying nociception and neuroinflammation ex vivo, and for preclinical development of novel therapeutics.​


Background

Controlling pain is a major challenge in clinical medicine. Animal models are used to understand the mechanisms of physiological and/or pathological pain and are always associated with severe suffering. These experiments, usually in rodents, not only require inducing pain by different physical or chemical approaches, but also, specifically when neuropathic or chronic pain is studied, the generation of nerve injury resulting in long lasting pain hypersensitivity. The difficulties in using animal models to study the circuitry and neurophysiology of nociceptors are widely documented (1). To bypass some of these difficulties, we have developed acute and organotypically cultured spinal cord slices and demonstrated that they can provide unique insight into the central mechanisms of nociception and neuroinflammation. The transient receptor potential cation channel vanilloid subfamily member 1 (TRPV1) is crucial to the onset of inflammation of peripheral tissues. We have characterized the response of spinal cord slices to challenge with capsaicin, a natural agonist of TRPV1 (2), and demonstrated its usefulness to model acute inflammation in central neurons (3).

The tool: We can obtain and apply acute and organotypically cultured postnatal (P7-P10) and young adult (P30) spinal cord slice preparations to the study of pain. The age of the donor is crucial (4) as the nociceptive system matures around P21 in rodents. The possibility to cultivate both immature and mature tissues offers unique opportunities to study the plasticity of neural circuits and their responses to inflammatory challenges. The principles of the preparation and use of the spinal cord slices as a platform for studying central pain signals are illustrated in Figure 1.

  Figure 1


Current state of the art

Research in the field of pain and neuroinflammation is currently conducted either in vivo or on isolated cells cultured in vitro. Although working in vivo offers the obvious advantage of maintaining an intact neuronal circuitry, this type of approach is technically very demanding and suffers from a high degree of variability in the nociceptive responses between individuals and sets of experiments. Additionally, drug bioavailability can be difficult to control and certain substances do not pass the blood-brain barrier, thus requiring spinal intrathecal administration, increasing complexity and welfare burden. Many of these shortcomings can be overcome using cultured primary neurons and/or neuronal cell lines, but circuitries are lost by this approach, rendering it unsuitable to the study of cell-to-cell communication and modulation of neural signals.

Spinal cord slices either maintained acutely in vitro or organotypically cultured offer several advantages for studying the structural, physiological and pharmacological properties of pain circuits. Because they retain the cytoarchitecture of the tissue of origin, slices have evolved as the predominant in vitro preparation used by electrophysiologists, and, although to a lesser extent, histologists, pharmacologists and biochemists. As slice-based assay systems provide good experimental access and allow precise control of extracellular environments, they facilitate research aiming to establish clear correlations between structure and function, as well as plasticity of neuronal interactions under different experimental conditions. 


What could your Solution be used for?

Our cultures can be easily subjected to a surrogate inflammatory challenge and the response of the synapses between first and second order nociceptive neurons can be monitored by bulk-load calcium imaging of their somas, patch-clamp electrophysiological recordings, or quantification of early gene (fos/erk) activation (5). The release of nociceptive mediators can be monitored by immunochemical procedures (e.g. ELISA or immunocytochemistry) (5). Notably, the system can be further manipulated by genetic engineering using a physical transfection method (gene-gun) that, at least in part, avoids the need to generate novel transgenic strains, further reducing the use of animals in these studies. Supporting this approach, we have recently developed an ex vivo FRET-based procedure that monitors caspase 3-dependent neurodegeneration in slice preparations, and can be used to test the effects of sustained inflammation on neuronal survival (6;7).

Our system is also amenable to pharmacological medium throughput screening as slices can be co-cultured with a biosensor cell line (“sniffer cell”) expressing receptors for an inflammatory factor of interest (Figure 2). This approach is crucial to test the physiological relevance of centrally released mediators of inflammation as it gives cues on their capability to elicit a functionally relevant response in vivo. Neurons derived from human-induced pluripotent stem cells can also be used as biosensor “sniffer” cells to obtain important translational information on the response of human neurons to slice-derived inflammatory mediators. By co-cultivating these cells with murine spinal cord slices subjected to experimental inflammation it will be possible to ascertain if molecules released by the spinal cord neural cells can indeed elicit a functional response on human neurons (8). In future work, we envisage developing a dorsal root ganglion-spinal cord co-culture system, to avoid the degeneration of sectioned primary afferents after a few days in culture and thus to enable longer-term studies.

  Figure 2


Need for collaboration

Collaborations are sought with academics and/or pharmaceutical and biotechnology companies to:

  • Expand (e.g. by the use of microfluidic culture systems) and validate SCSPs for preclinical drug development and precision medicine.
  • Provide a larger panel of candidate pain-controlling drugs/molecules that could be tested and shortlisted for further development using SCSPs.
  • Explore the utility of the slice model for investigating disease models, for example using the spinal cord of an EAE mouse to study Multiple Sclerosis.

In the framework of a collaborative project/venture, we offer:

  • The possibility to test any compound of interest with our SCSPs.
  • The development of slice platforms from other areas of CNS (postnatal cerebellar slices are already routinely in use in the lab) for the study of neurodegeneration.
  • The development of slice platforms from aged brains. 

3Rs impact assessment

Using SCSPs has the potential to reduce the number of animals used in experiments by:

  • Enabling multiple slices to be obtained from each animal, therefore decreasing the number of animals required per study. As an example, 20 slices (400 µm thick) can be easily obtained after dissection of the spinal cord from a P4 mouse. Multiple slices can be cultured in each well of a multi-well plate, enabling different experimental/pharmacological challenges to be performed on SCSPs obtained from the same animals (Figure 3). In an in vivo approach where eight mice were used per group, and four groups studied, SCSPs have the potential to reduce the number of mice used from 32 to 8. The technology also provides a novel medium throughput screening platform amenable to preclinical development of pain-targeted therapeutics.
  • Avoiding the need to specifically generate new transgenic mouse strains. SCSPs can be transiently transfected to express one or more proteins of interest, removing the requirement to breed transgenic animals for some experiments.

  Figure 3

For more information or to contact the Solution provider: www.morfovet.it/Merighi/Index.html


References

  1. Mao J. Current challenges in translational pain research. Trends Pharmacol Sci 2012 Nov;33(11):568-73.
  2. Ferrini F, Russo A, Salio C. Fos and pERK immunoreactivity in spinal cord slices: Comparative analysis of in vitro models for testing putative antinociceptive molecules. Annals of Anatomy - Anatomischer Anzeiger 2014 Jul;196(4):217-23.
  3. Frias B, Merighi A. Capsaicin, Nociception and Pain. Molecules 2016;21:797.
  4. Jackson SJ, Andrews N, Ball D, Bellantuono I, Gray J, Hachoumi L, et al. Does age matter? The impact of rodent age on study outcomes. Laboratory Animals 2016 Jun 15.
  5. Salio C, Ferrini F, Muthuraju S, Merighi A. Presynaptic modulation of spinal nociceptive transmission by glial cell line-derived neurotrophic factor (GDNF). J Neurosci 2014 Oct 8;34(41):13819-33.
  6. Alasia S, Cocito C, Merighi A, Lossi L. Real time visualization of caspase-3 activation by fluorescence resonance energy transfer (FRET). In: Lossi L, Merighi A, editors. Neuronal cell death.New York: Humana Press/Springer Science+Business Media; 2015. p. 99-114.
  7. Lossi L, Cocito C, Alasia S, Merighi A. Ex vivo imaging of active caspase 3 by a FRET-based molecular probe demonstrates the cellular dynamics and localization of the protease in cerebellar granule cells and its regulation by the apoptosis-inhibiting protein survivin. Molecular Neurodegeneration 2016;11(1):1-20.
  8. Ghoochani A, Yakubov E, Sehm T, Fan Z, Hock S, Buchfelder M, et al. A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain. Oncotarget 2016 Jan 12;7(2):1838-53.

Additional information

University of Turin flyer

Back to top

Solution provider

You must be logged in to contact Solution providers.

Login | Register